U.S. markets close in 3 hours 6 minutes

Biora Therapeutics, Inc. (BIOR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.1482-0.0018 (-0.16%)
As of 12:50PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close1.1500
Bid1.1400 x 1000
Ask1.1500 x 2200
Day's Range1.0600 - 1.1600
52 Week Range1.0600 - 7.6800
Avg. Volume476,060
Market Cap27.217M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-10.1600
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BIOR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biora Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/13/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    It’s the final day of trading this week and we’re starting it with a breakdown of the biggest pre-market stock movers on Friday morning! Moving stocks this morning are updates from the U.S. Food and Drug Administration (FDA), public share offerings and more. Let’s get into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Green Giant (NASDAQ:GGE) stock is rocketing more than 108% after revealing details of its 2023 Equi

  • GlobeNewswire

    Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

    BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative col

  • Insider Monkey

    Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Call Transcript

    Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Call Transcript November 13, 2023 Biora Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-4.89 EPS, expectations were $-0.93. Operator: Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call. At this time, all participants are in a listen only mode. A brief question-and-answer session […]